Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer
作者:Qingna Jiang、Minghai Fu、Yuanling Tang、Ge Li、Guihui Tu、Xinhua Wu、Qiurong Wu、Xiuwang Huang、Jianhua Xu、Yang Liu、Lixian Wu
DOI:10.1016/j.ejmech.2023.115690
日期:2023.11
proteins. Hsp90α, the major isoform of Hsp90, can promote tumour cell migration and metastasis, and is abundantly secreted in highly invasive tumours. To date, most pan-Hsp90 inhibitors have been limited in their applications due to high toxicity. Herein, we described the candidate compound X10g based on a proteolysis-targeting chimaera (PROTAC) strategy that potently and selectively degraded Hsp90α. The
热休克蛋白90(Hsp90)是一种高度保守、广泛表达的分子伴侣,主要负责维持客户蛋白的正确折叠,与肿瘤相关蛋白的稳定性和激活密切相关。Hsp90α是Hsp90的主要亚型,可以促进肿瘤细胞迁移和转移,并且在高侵袭性肿瘤中大量分泌。迄今为止,大多数泛Hsp90抑制剂由于毒性较高而限制了其应用。在此,我们描述了基于蛋白水解靶向嵌合体 (PROTAC) 策略的候选化合物X10g ,该策略可有效且选择性地降解 Hsp90α。结果表明,X10g具有较好的抑制肿瘤作用,且体内毒性较低。这些发现表明,合成的选择性 Hsp90α 降解剂X10g为乳腺癌治疗提供了新策略。